Last updated: February 25, 2026
What is the drug identified by NDC 69367-0430?
NDC 69367-0430 corresponds to Tucatinib, marketed under the brand name Tukysa. Tucatinib is a tyrosine kinase inhibitor targeting HER2, approved by the FDA in April 2020 for treating HER2-positive advanced unresectable or metastatic breast cancer.
Market Size and Growth Drivers
Approved Indications and Patient Population
The primary indication for Tucatinib is HER2-positive breast cancer, with an estimated patient population in the US of approximately 300,000. According to the American Cancer Society (2022), roughly 15-20% of breast cancers overexpress HER2, translating to about 45,000 newly diagnosed cases annually, with a subset eligible for Tucatinib treatment.
Competitive Landscape
Tucatinib competes primarily with other HER2-targeted therapies including:
- Trastuzumab (Herceptin)
- Pertuzumab
- Ado-trastuzumab emtansine (Kadcyla)
- Neratinib
- Pyrotinib (approved in China)
Market penetration depends on line of therapy, combination regimens, and emerging data.
Revenue Estimates
In its launch year (2020-2021), Tucatinib generated approximately $63 million in US sales (Evaluate Pharma). Projected growth reflects increased adoption in second-line and later therapy settings, with forecasted revenue reaching $300 million globally by 2025.
Market Growth Rate
The HER2-positive breast cancer treatment market is forecasted to grow at an annual rate (CAGR) of 8-10% from 2022-2027, driven by:
- Expanded indications
- Increasing treatment adoption
- Competitive advancements
Geographic Expansion Opportunities
The drug has FDA approval in the US. Regulatory submissions in Europe and Asia are underway or completed, with potential access expanding to markets representing an additional 1.2 billion patients globally, depending on local regulatory approval timelines.
Price Projections and Cost Analysis
Current Pricing
As of Q1 2023, the wholesale acquisition cost (WAC) for Tucatinib is approximately $8,500 per 30-count blister pack (30 mg capsules), translating to roughly $283 per capsule. The typical regimen involves dosing twice daily, 50 mg or 60 mg depending on tolerance, for a course lasting 3-6 months.
Comparative Pricing
Compared with other HER2-targeted agents:
| Drug |
WAC per month |
Indication |
Notes |
| Tucatinib (Tukysa) |
$8,500 |
HER2-positive breast cancer |
Capsule form, oral |
| Trastuzumab (Herceptin) |
$5,000-$7,000 |
Multiple HER2 indications |
IV infusion, high costs |
| Ado-trastuzumab emtansine |
$9,000 |
HER2-positive metastatic breast cancer |
Intravenous, fixed dose |
Price Trends
Price stability is expected over the next 12-24 months, with potential decreases if biosimilars or generics enter the market, though biologic status complicates biosimilar development.
Cost-Effectiveness and Insurance Coverage
Tucatinib’s cost-effectiveness metrics, consultative with private insurers and Medicare, suggest reimbursement levels around 85-90%. Ongoing comparative effectiveness studies could influence pricing adjustments.
Future Price Dynamics
- Potential Biosimilar Competition: Biosimilar HER2 inhibitors may emerge within 3-5 years, pressuring prices downward.
- Market Expansion: Increased global use, especially in Europe and Asia, could stabilize pricing through volume growth.
- Policy Changes: Negotiations of drug prices under Medicare and private plans may influence future retail prices.
Key Takeaways
- Tucatinib targets a niche within HER2-positive breast cancer, with a market share expected to expand to nearly $300 million globally by 2025.
- Current global prices at roughly $8,500 per month reflect its positioning as an oral targeted therapy.
- Competition and biosimilar development threaten potential price reductions.
- Price stability hinges on regulatory approvals outside the US, market penetration, and patent protections.
Frequently Asked Questions
How does Tucatinib compare to other HER2-targeted therapies in price and efficacy?
Tucatinib is typically less expensive monthly than some intravenous agents like Ado-trastuzumab emtansine but comparable in cost to trastuzumab, with a comparable efficacy profile in specific indications.
When can we expect biosimilars or generics for Tucatinib?
As a small-molecule kinase inhibitor, Tucatinib is not biologic. No biosimilar pathway exists; but generics may emerge in 5-7 years if patent protections expire or are challenged.
What are the key factors influencing Tucatinib’s pricing?
Patent exclusivity, competitive landscape, global approval status, and negotiation power with payers.
How will recent clinical trial outcomes impact the market?
Positive trial results expanding indications or demonstrating superior efficacy could drive market share and revenue, influencing pricing strategies.
What are the regulatory hurdles for expanding Tucatinib’s use internationally?
Approval depends on local health agencies reviewing trial data; development of robust local dossiers and clinical trial programs are necessary steps.
References
[1] American Cancer Society. (2022). Breast Cancer Facts & Figures 2022-2023.
[2] Evaluate Pharma. (2022). Oncology Market Reports.
[3] U.S. Food and Drug Administration. (2020). FDA approves Tucatinib for HER2-positive breast cancer.
